DAXOR ANNOUNCES KEY MILESTONES ACHIEVED FOR MULTICENTER BVA-100® STUDY IN HOSPITALIZED PATIENTS WITH COVID-19
05. Januar 2022 08:00 ET
|
Daxor Corporation
Patient Enrollment Complete and Data Analysis Commences with Daxor’s Blood Volume Analysis Technology Oak Ridge, TN, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the...
Ritter Pharmaceuticals Initiates First Pivotal Phase 3 Trial for RP-G28 for the Treatment of Lactose Intolerance
27. Juni 2018 07:00 ET
|
Ritter Pharmaceuticals, Inc.
Conference Call Today - June 27, 2018 at 4:30 p.m. ET LOS ANGELES , June 27, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a...